AbbVie has expanded the availability of SKYRIZI in Canada for ulcerative colitis, strengthening its presence in the ...
Aldeyra's reproxalap faced an FDA setback but showed positive trial results, leading to a resubmitted NDA. Click here to find ...
Zacks Investment Research on MSN18h
Here's How to Play AbbVie Stock as it Enters the Obesity SpaceAbbVie ABBV announced that it is in-licensing rights to develop phase I candidate, GUB014295, a long-acting amylin analog for ...
Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...
In a report released today, Mohit Bansal from Wells Fargo maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of ...
Pfizer reacts to Donald Trump’s tariff threats on big pharma, another regulatory meeting is canceled under RFK Jr., AbbVie ...
Bank of America raised AbbVie’s price target from $200 to $223 while maintaining a neutral rating. Other analysts have also ...
AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra's obesity drug. AI takes center stage at HIMSS ...
The stock's fall snapped a three-day winning streak.
Cosmetic drugmaker Evolus reported a fourth-quarter profit versus a year-ago loss on Tuesday, on strong demand for its wrinkle treatment Jeuveau which competes with Botox.
The Trump administration is engaged in a effort to slash the federal government workforce. Military veterans make up nearly a ...
AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback